Results 81 to 90 of about 37,430 (216)

Reversible pulmonary toxicity due to lenalidomide

, 2011
Lenalidomide is a derivative of thalidomide and is FDA-approved for the treatment of myelodysplastic syndrome and, in combination with dexamethasone, for the treatment of relapsed multiple myeloma.
Stephanie Coates, Stephen Spurgeon, Alan Barker   +2 more
core   +1 more source

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes

, 2014
Abdallah Abou Zahr,1 Ehab Saad Aldin,2 Rami S Komrokji,3 Amer M Zeidan4 1Section of Hematology/Oncology, Department of Internal Medicine, Mount Sinai Beth Israel, New York City, New York, NY, 2Department of Internal Medicine, Medstar Good Samaritan ...
Zeidan AM, Abou Zahr A, Saad Aldin E, Komrokji RS   +3 more
core  

Improving the Solubility of Lenalidomide via Cocrystals

, 2016
An anticancer drug, lenalidomide, has low oral bioavailability (below 33%) due to its poor solubility in water. To improve its solubility, three cocrystals of lenalidomide with urea (1) and 3,5-dihydroxybenzoic acid (2, 3) were prepared.
Tong-Bu Lu (1516030), Jia-Xi Song (1516024), Yan Yan (208529), Jia Yao (323339), Jia-Mei Chen (1516027)   +4 more
core   +1 more source

Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis

, 2018
Chun-Hong Xie, Min Wei, Fei-Yan Yang, Fu-Zhen Wu, Lei Chen, Jian-Kun Wang, Qin Liu, Jin-Xiong Huang Department of Hematology, Affiliated Liuzhou People’s Hospital of Guangxi University of Science and Technology (Liuzhou People’s Hospital ...
Huang JX, Xie CH, Wei M, Chen L, Wu FZ, Liu Q, Yang FY, Wang JK   +7 more
core  

Lenalidomide for bortezomib- resistant Multiple Myeloma

, 2010
We read with great interest the paper by Ludwig and Zojer reporting a patient with bortezomib-resistant multiple myeloma who achieved renal recovery after lenalidomide therapy.
BERNO T, ZAMBELLO R., BRIANI, CHIARA, CAMPAGNOLO M   +3 more
core   +1 more source

Lenalidomide regulates CNS autoimmunity by promoting M2 macrophages polarization [PDF]

, 2018
Multiple sclerosis (MS) is a chronic and debilitating neurological disorder of the central nervous system (CNS), characterized by infiltration of leukocytes into CNS and subsequent demyelination.
Fahmida Sattar, Sattar, F., Bo Yang, Hao, G., Weng, Q., Liu, X., Xu, Z., Jiahuan Zheng, Wang, J., Lijun Yang, Yang, L., He, Q., Mengting Zhao, Zhao, M., Zhikang Zhang, Qinjie Weng, Guifeng Hao, Jiajia Wang, Xuan Liu, Lu, Q.R., Zijie Xu, Fang, L., Jing Wang, Zhang, Z., Q. Richard Lu, Liang Fang, Jiaying Wang, Qiaojun He, Zheng, J., Yang, B.   +29 more
core   +1 more source

Secondary B-acute lymphoblastic leukemia following lenalidomide maintenance in multiple myeloma

Indian Journal of Pathology and Microbiology
Following the advent of immunomodulatory agents (IMiDs) in the treatment of multiple myeloma (MM), the progression-free survival has improved significantly.
Raghuveer S. Prabhu, R Pranav, Jay Mehta
doaj   +1 more source

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM

Blood Advances, 2018
: Autologous stem cell transplantation (ASCT) followed by lenalidomide maintenance therapy is the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM).
Sundar Jagannath, Rafat Abonour, Brian G.M. Durie, Mohit Narang, Howard R. Terebelo, Cristina J. Gasparetto, Kathleen Toomey, James W. Hardin, Lynne Wagner, Amit Agarwal, Shankar Srinivasan, Amani Kitali, E. Dawn Flick, Michael Sturniolo, Robert M. Rifkin   +14 more
doaj   +1 more source

Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study

British Journal of Haematology, EarlyView.
Summary While marginal zone lymphoma (MZL) is generally indolent, outcomes following relapse remain poorly defined. This study utilized the indolent Non Follicular 10 (NF10) prospective database to characterize survival and identify prognostic drivers in patients failing initial systemic therapy. The study analysed 122 patients with relapsed MZL.
Stefano Luminari, Maria Elena Nizzoli, Michele Merli, Sara Rattotti, Vittoria Tarantino, Simone Ferrero, Annalisa Talami, Roberta Murru, Marina Deodato, Emanuele Cencini, Giovanni Roti, Carlo Visco, Guilherme Duffles, Michele Spina, Ombretta Annibali, Alessandro Pulsoni, Andrés José María Ferreri, Caterina Stelitano, Elsa Pennese, Emiliano Barbieri, Marzia Varettoni, Gambara Silvia, Marta Coscia, Dario Marino, Tisi Maria Chiara, Maher Nawar, Luigi Marcheselli, Francesco Merli, Luca Arcaini   +28 more
wiley   +1 more source

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment [PDF]

, 2017
Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide-dexamethasone (Rd) for relapsed or refractory multiple myeloma.
L Rosiñol, P Rajnics, Hajek R, Suvorov A, Aggarwal S, Mihaylov GG, S Aggarwal, Siegel D, San-Miguel J, Moreau P, Rosinol L, V Goranova-Marinova, J San-Miguel, A K Stewart, T Masszi, Oriol A, Stewart AK, G G Mihaylov, Dimopoulos MA, A Oriol, A Suvorov, Spicka I, H Ludwig, I Špička, P Moreau, A Palumbo, Rajnics P, Palumbo A, D Siegel, Jakubowiak A, S Ro, Goranova-Marinova V, R Hájek, M A Dimopoulos, Niesvizky R, Ro S, A Jakubowiak, Ludwig H, R Niesvizky, Masszi, Tamás   +39 more
core   +1 more source